Reske SN - Search Results

1

New molecular markers for prostate tumor imaging: a study on 2-methylene substituted fatty acids as new AMACR inhibitors.

Morgenroth A, Urusova EA, Dinger C, Al-Momani E, Kull T, Glatting G, Frauendorf H, Jahn O, Mottaghy FM, Reske SN, Zlatopolskiy BD. Morgenroth A, et al. Among authors: reske sn. Chemistry. 2011 Aug 29;17(36):10144-50. doi: 10.1002/chem.201003176. Epub 2011 Aug 2. Chemistry. 2011. PMID: 21812041

2

Towards to hENT1-nucleoside transporter selective imaging agents. Synthesis and in vitro evaluation of the radiolabeled SAENTA analogues.

Zlatopolskiy BD, Morgenroth A, Urusova EA, Dinger C, Kull T, Pape M, Glatting G, Reske SN. Zlatopolskiy BD, et al. Among authors: reske sn. Bioorg Med Chem Lett. 2009 Sep 1;19(17):5151-4. doi: 10.1016/j.bmcl.2009.07.017. Epub 2009 Jul 9. Bioorg Med Chem Lett. 2009. PMID: 19632836

3

Synthesis and biologic study of IV-14, a new ribonucleoside radiotracer for tumor visualization.

Zlatopolskiy BD, Morgenroth A, Kunkel FH, Urusova EA, Dinger C, Kull T, Lepping C, Reske SN. Zlatopolskiy BD, et al. Among authors: reske sn. J Nucl Med. 2009 Nov;50(11):1895-903. doi: 10.2967/jnumed.109.065623. Epub 2009 Oct 16. J Nucl Med. 2009. PMID: 19837748 Free article.

4

[11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy.

Reske SN, Blumstein NM, Glatting G. Reske SN, et al. Eur J Nucl Med Mol Imaging. 2008 Jan;35(1):9-17. doi: 10.1007/s00259-007-0530-2. Epub 2007 Sep 9. Eur J Nucl Med Mol Imaging. 2008. PMID: 17828534

5

Comparing time activity curves using the Akaike information criterion.

Kletting P, Kull T, Reske SN, Glatting G. Kletting P, et al. Among authors: reske sn. Phys Med Biol. 2009 Nov 7;54(21):N501-7. doi: 10.1088/0031-9155/54/21/N01. Epub 2009 Oct 9. Phys Med Biol. 2009. PMID: 19820266

6

[PET and PET/CT in relapsing prostate carcinoma].

Reske SN, Blumstein NM, Glatting G. Reske SN, et al. Urologe A. 2006 Oct;45(10):1240, 1242-4, 1246-8, 1250. doi: 10.1007/s00120-006-1212-6. Urologe A. 2006. PMID: 17006698 Review. German.

7

Determination of individual organ masses for (90)Y-anti-CD66 radioimmunotherapy: influence on therapy planning.

Kull T, Kletting P, Reske SN, Glatting G. Kull T, et al. Among authors: reske sn. Z Med Phys. 2011 Dec;21(4):305-9. doi: 10.1016/j.zemedi.2011.05.003. Epub 2011 Jun 29. Z Med Phys. 2011. PMID: 21719265

8

Optimal preloading in radioimmunotherapy with anti-cD45 antibody.

Kletting P, Kull T, Bunjes D, Luster M, Reske SN, Glatting G. Kletting P, et al. Among authors: reske sn. Med Phys. 2011 May;38(5):2572-8. doi: 10.1118/1.3581059. Med Phys. 2011. PMID: 21776793

9

Determination of the immunoreactivity of radiolabeled monoclonal antibodies: a theoretical analysis.

Glatting G, Reske SN. Glatting G, et al. Among authors: reske sn. Cancer Biother Radiopharm. 2006 Feb;21(1):15-21. doi: 10.1089/cbr.2006.21.15. Cancer Biother Radiopharm. 2006. PMID: 16480327

10

Dependence of the anti-CD66 antibody biodistribution on the dissociation constant: a simulation study.

Kletting P, Reske SN, Glatting G. Kletting P, et al. Among authors: reske sn. Z Med Phys. 2011 Dec;21(4):301-4. doi: 10.1016/j.zemedi.2011.03.003. Epub 2011 May 6. Z Med Phys. 2011. PMID: 21530196

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

275 results

Search Page

Filters